Forteo

Low Testosterone, Osteoporosis, Osteoporosis + 1 more

Treatment

8 FDA approvals

20 Active Studies for Forteo

What is Forteo

Teriparatide

The Generic name of this drug

Treatment Summary

Teriparatide is a medication manufactured by Eli Lilly and Company that is used to strengthen bones in patients with osteoporosis. It is a form of recombinant human parathyroid hormone, which helps to stimulate bone growth.

Forteo

is the brand name

image of different drug pills on a surface

Forteo Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Forteo

Teriparatide

2002

4

Approved as Treatment by the FDA

Teriparatide, otherwise called Forteo, is approved by the FDA for 8 uses which include Osteoporosis and Hypogonadism .

Osteoporosis

Helps manage Osteoporosis

Hypogonadism

Helps manage Hypogonadism

Primary Osteoporosis

Helps manage Primary Osteoporosis

Osteoporosis caused by glucocorticoid

Helps manage Osteoporosis caused by glucocorticoid

Osteoporosis

Helps manage Osteoporosis

Osteoporosis

Helps manage Osteoporosis caused by glucocorticoid

Osteoporosis

Helps manage Primary Osteoporosis

Low Testosterone

Helps manage Hypogonadism

Effectiveness

How Forteo Affects Patients

Teriparatide is a synthetic hormone that helps to create new bone in men and women. It increases the amount of bone in your body, increases markers of bone growth, and makes your bones stronger. Taking teriparatide also temporarily increases the amount of calcium in your blood and increases the amount of calcium your body gets rid of in your urine. It can also cause your body to get rid of more phosphorus, which can lead to a drop in phosphorus levels in your blood.

How Forteo works in the body

Parathyroid hormone (PTH) is a hormone that helps to regulate calcium and phosphate levels in the body. Excess PTH can break down bones. Teriparatide is a synthetic form of PTH that works differently from regular PTH. It stimulates new bone growth, rather than breaking down existing bones. It does this by binding to PTH type 1 receptors, which are found on osteoblasts, osteocytes, and kidney cells. This binding triggers pathways in the body that stimulate bone growth and reduce bone breakdown. It also increases the expression of certain proteins that help promote bone growth and decrease proteins that inhibit bone growth.

When to interrupt dosage

The measure of Forteo is contingent upon the diagnosed affliction, including Osteoporosis brought about by glucocorticoid, Osteoporosis and Low Testosterone. The amount also fluctuates as per the technique of delivery (e.g. Subcutaneous or Solution) delineated in the table beneath.

Condition

Dosage

Administration

Low Testosterone

, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL

Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous

Osteoporosis

, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL

Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous

Osteoporosis

, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL

Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous

Osteoporosis

, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL

Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous

Warnings

There are 20 known major drug interactions with Forteo.

Common Forteo Drug Interactions

Drug Name

Risk Level

Description

Acetohexamide

Minor

The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Teriparatide.

Carbutamide

Minor

The therapeutic efficacy of Carbutamide can be decreased when used in combination with Teriparatide.

Chlorpropamide

Minor

The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Teriparatide.

Glibornuride

Minor

The therapeutic efficacy of Glibornuride can be decreased when used in combination with Teriparatide.

Gliclazide

Minor

The therapeutic efficacy of Gliclazide can be decreased when used in combination with Teriparatide.

Forteo Toxicity & Overdose Risk

The lethal dose of teriparatide when given subcutaneously or intravenously in rats is 1000µg/m3 and 300µg/m3, respectively. In rare cases, people have accidentally been given 40 times the recommended dose of 800mcg, which resulted in nausea, weakness, lethargy, and low blood pressure. As there is no antidote for an overdose, treatment should involve stopping the teriparatide and monitoring calcium and phosphorus levels in the blood, as well as providing supportive measures such as hydration.

image of a doctor in a lab doing drug, clinical research

Forteo Novel Uses: Which Conditions Have a Clinical Trial Featuring Forteo?

62 active studies are being conducted to assess the potential of Forteo to alleviate Osteoporosis, Low Testosterone and related Osteoporotic conditions.

Condition

Clinical Trials

Trial Phases

Osteoporosis

25 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 2

Low Testosterone

4 Actively Recruiting

Phase 1, Phase 4, Phase 2, Phase 3

Osteoporosis

0 Actively Recruiting

Osteoporosis

0 Actively Recruiting

Forteo Reviews: What are patients saying about Forteo?

5

Patient Review

6/3/2019

Forteo for Decreased Bone Mass Following Menopause

I was so pleased with the results of this treatment. It not only repaired my broken bones, but it also strengthened the surrounding areas to prevent any future breakage.

4.7

Patient Review

3/31/2019

Forteo for Osteoporosis in Male Patient

The injection was simple, but I experienced stomach cramps about 20 minutes later.

4

Patient Review

4/19/2021

Forteo for osteoporosis in postmenopausal woman at high risk for fracture

I've had no issues with side effects and the needle injections are really not that bad. After one year of treatment, I saw a significant improvement in my bone density test results. Hoping for similar results this coming May from my second-year tests.

3.7

Patient Review

11/30/2020

Forteo for Decreased Bone Mass Following Menopause

I took this medication for 18 months before I stopped. I gained weight while on it, but eventually got tired of having to inject myself daily. I then switched to Evista for a couple years, which helped me lose the weight again. However, now that I'm back on Forteo (for the final 6 months that my insurance will cover), I've been having problems with my memory. Not sure if it's related to the drug or not...

3

Patient Review

7/8/2020

Forteo for Decreased Bone Mass Following Menopause

I am on my fourth month of Forteo for osteoporosis prevention. So far, no fractures or broken bones. I walk 4 miles several times a week and don't have any other health issues. However, by the third month, I started feeling occasional nausea which quickly became constant fatigue. I messaged my doctor and will now inject every other day to see if I can tolerate it better. My non-fasting lab showed elevated glucose of 145 which is new for me.

3

Patient Review

4/22/2020

Forteo for osteoporosis in postmenopausal woman at high risk for fracture

I've been using Forteo for a year now. My L spine was -3.7 a year ago and it's only at -3.1 now, which isn't that great of an improvement. My femur went from -1.5 to -2.4, so there hasn't been much progress there either unfortunately..

2.7

Patient Review

7/27/2020

Forteo for Decreased Bone Mass Following Menopause

Since beginning this treatment, I've experienced an increase in pain and nausea with each injection. I'm now trying to every third day in order to try and get some benefit for my bones. The side effects are really taking a toll though.

2.3

Patient Review

2/14/2019

Forteo for Osteoporosis in Male Patient

I did not experience any benefits from this medication, and unfortunately about three months after starting the shots I lost a tooth. Be aware of the potential side effects before trying this treatment.

2

Patient Review

9/6/2022

Forteo for Osteoporosis in Male Patient

After just a few doses, I started having excruciating pain in my knee and leg. It got so bad that I couldn't walk without assistance. Needless to say, I stopped taking the medication and feel like I wasted a ton of money. Now, I don't know what to do about my osteoporosis.

1.7

Patient Review

11/11/2022

Forteo for osteoporosis in postmenopausal woman at high risk for fracture

The last unit I received was defective, and when I contacted the company they gave me a run-around rather than taking responsibility. It's hard enough to use this product as it is; having to deal with customer service on top of that is really frustrating.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about forteo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the dangers of Forteo?

"One common side effect of this medication is feeling faint, tired, or confused."

Answered by AI

Is Forteo a daily injection?

"Forteo is typically given as a single daily injection beneath the skin. A common dosage is 20 micrograms (mcg) once per day."

Answered by AI

Does Forteo build bone?

"Forteo is a medication used to treat osteoporosis. It is a synthetic version of the human parathyroid hormone, which promotes the growth of new bone. Other osteoporosis medications work by inhibiting bone resorption, or breakdown."

Answered by AI

What does the drug Forteo do?

"Forteo (teriparatide injection) can reduces your risk of another fracture. It is a prescription medicine used to treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments."

Answered by AI

Clinical Trials for Forteo

Image of Clinical and Translational Science Center, Weill Cornell Medical College in New York, United States.

Treatment for Menopause

40 - 90
Female
New York, NY

This study will compare adherence, tolerability, safety, and treatment satisfaction between a calcium-rich food and a traditional calcium carbonate supplement in women ages 40 to 90 who are at increased risk for osteoporosis. Participants will be randomly assigned to receive either a calcium-rich food providing 500 mg of calcium from milk-derived minerals or a 500 mg calcium carbonate supplement once daily for four weeks. Participants will complete brief weekly questionnaires assessing supplement use, gastrointestinal symptoms, and treatment satisfaction. The goal of the study is to determine whether the form in which calcium is consumed influences adherence and participant experience. No blood draws, imaging studies, or other invasive procedures are involved

Waitlist Available
Has No Placebo

Clinical and Translational Science Center, Weill Cornell Medical College

Jeff Zhu

Image of Rocky Mountain Regional VA Medical Center, Aurora, CO in Aurora, United States.

Testosterone Therapy for Spinal Cord Injury

18+
Male
Aurora, CO

Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.

Phase 2 & 3
Waitlist Available

Rocky Mountain Regional VA Medical Center, Aurora, CO (+3 Sites)

Joshua F Yarrow, PhD MS BS

Have you considered Forteo clinical trials?

We made a collection of clinical trials featuring Forteo, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Recruiting
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Precision IO Group

Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD

Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.

Recruiting
Has No Placebo

University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)

Denise Orwig, PhD

Have you considered Forteo clinical trials?

We made a collection of clinical trials featuring Forteo, we think they might fit your search criteria.
Go to Trials
Image of Neuromuscular Research Laboratory in Pittsburgh, United States.

Hormone Therapy for Musculoskeletal Health

18 - 40
All Sexes
Pittsburgh, PA

Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps. The goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.

Phase 4
Recruiting

Neuromuscular Research Laboratory

Bradley C Nindl, PhD

Image of Marcus Institute for Aging Research, Hebrew SeniorLife in Boston, United States.

Injury Prevention Care Models for Osteoporosis

65+
All Sexes
Boston, MA

The goal of this clinical trial is to compare three care models for optimizing medications and preventing falls with broken bones in patients receiving rehabilitation after a hospitalization for a broken bone. The primary outcome is injurious falls, with secondary outcomes measuring how the process of care is changed and capturing patient-reported outcomes valued by stakeholders. The main questions this study aims to answer are: * Which of the three models is more effective in preventing falls with fractures? * What are the differences in patient-centered outcomes amongst the three models? These include pain, depression, anxiety, sleep, medication side effect burden, and fear of falling. * What are the differences in osteoporosis treatment and medication burden? The three care models are: a Deprescribing Care Model designed to reduce or stop fall-related medications, a Bone Heath Service Model designed to provide osteoporosis evaluation and management, and an Injury Prevention Service Model offering both services. 42 SNFs will participate in this study. The three models will be incorporated into the routine care of patients at these facilities who are receiving rehabilitation after a hospitalization for a fracture. All care models will be delivered remotely to patients in the SNF and after they transition home by a post-fracture nurse consultant supported by an interprofessional team. This study has three aims. See Detailed Description for more details. This ClinicalTrials.gov record represents the Comparative Effectiveness Aim of the protocol.

Waitlist Available
Has No Placebo

Marcus Institute for Aging Research, Hebrew SeniorLife (+1 Sites)

Cathleen S Colon-Emeric, MD, MHS

Have you considered Forteo clinical trials?

We made a collection of clinical trials featuring Forteo, we think they might fit your search criteria.
Go to Trials